Author Archives: admin1

Cardiac sarcoidosis resolved with Mycobacterium avium paratuberculosis antibiotics (MAP)

Posted on by

“After successful culture and identification of viable MAP in [the patient’s] blood, treatment with the MAP antibiotic regime for one year led to complete metabolic resolution of the previously avid cardiac sarcoidosis and no PET evidence of any metabolically active sarcoidosis anywhere. Such reversal of cardiac sarcoidosis has never previously been reported.”

Read more

 

Mycobacterium avium subspecies paratuberculosis: A possible causative agent in human morbidity and risk to public health safety

Posted on by

Here, the author presents current information assessing the link between numerous diseases states in humans such inflammatory bowel disease, Type 1 diabetes, rheumatoid arthritis, Hashimoto’s thyroiditis, multiple sclerosis and autism following infection with Mycobacterium avium paratuberculosis. The possibility of zoonotic transmission of the organism and its significant risk to public health safety as a consequence is also discussed.

Mary Garvey, Department of Life Science, Institute of Technology Sligo, Ash lane, Sligo, Ireland

June 2018

 

 

 

 

Knowledge gaps that hamper prevention and control of Mycobacterium avium subspecies paratuberculosis infection

Posted on by

Nearly a century of JD control programmes has, particularly in the dairy industry, not resulted in sufficient progress. Except for goats in Norway, no reports can be found in a herd in which MAP infection has been eradicated, and in many countries, herd- and animal-level prevalence has not decreased…

…Uptake of JD control programmes will improve if [the knowledge gaps identified by Barkema et al] have been satisfactorily addressed. However, because of the voluntary nature of JD programmes, it will still be important to identify factors that motivate farmers to enrol in these programmes.

https://onlinelibrary.wiley.com/doi/pdf/10.1111/tbed.12723

May 2017